Tyr402
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr402  -  Pyk2 (human)

Site Information
CsIEsDIyAEIPDEt   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447955
Associated spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 8 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 10 , 11 , 13 , 14 , 15 , 16 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 29 , 30 , 33 , 34 , 35 , 36 , 37 , 39 , 43 ) , mutation of modification site ( 1 , 38 , 41 , 45 , 46 , 47 , 57 , 58 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 8 , 9 , 12 , 17 , 18 , 19 , 20 , 31 , 32 , 38 , 40 , 41 , 42 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 8 , 9 , 12 , 17 , 18 , 19 , 20 , 31 , 32 , 41 , 42 , 44 , 45 , 46 , 53 , 54 , 55 , 56 , 57 , 58 )
Disease tissue studied:
adrenal cancer ( 8 , 45 ) , pheochromocytoma ( 8 , 45 ) , bladder cancer ( 36 ) , bone cancer ( 12 ) , breast cancer ( 1 , 4 , 58 ) , colorectal cancer ( 12 ) , colorectal carcinoma ( 12 ) , gastric carcinoma, surrounding tissue ( 24 ) , leukemia ( 10 , 11 , 19 , 30 , 33 , 34 , 35 , 37 , 39 , 41 ) , acute lymphocytic leukemia ( 35 , 37 ) , acute myelogenous leukemia ( 33 , 34 , 39 ) , chronic myelogenous leukemia ( 10 , 11 , 19 , 30 , 41 ) , lung cancer ( 9 , 13 , 14 , 15 , 18 , 44 ) , non-small cell lung cancer ( 9 , 13 , 14 , 15 , 18 ) , non-small cell lung adenocarcinoma ( 9 , 13 , 14 , 15 ) , lymphoma ( 20 ) , T cell lymphoma ( 20 ) , thymic carcinoma ( 16 ) , rheumatoid arthritis ( 31 ) , SLE ( 31 )
Relevant cell line - cell type - tissue:
'neuron, cortical'-brain ( 5 ) , 293 (epithelial) ( 2 , 45 , 58 ) , 5637 (bladder cell) ( 36 ) , A431 (epithelial) ( 49 ) , A549 (pulmonary) ( 44 ) , BAEC (endothelial) ( 53 ) , DU4475 (breast cell) ( 51 ) , H9c2 (myoblast) ( 2 ) , HCT116 (intestinal) ( 12 ) , HEK293T (epithelial) ( 1 , 5 , 46 ) , HeLa (cervical) ( 12 , 49 ) , HMVEC (endothelial) ( 47 ) , HUT-78 (T lymphocyte) ( 20 ) , HUVEC (endothelial) ( 38 , 40 , 47 ) , Jurkat (T lymphocyte) ( 20 , 21 , 22 , 23 , 25 , 26 , 27 , 29 , 43 , 52 , 57 ) , K562 (erythroid) ( 10 , 11 , 19 , 30 , 41 , 50 ) , KG-1 (myeloid) ( 48 ) , lung ( 13 , 14 , 15 ) , MCF-7 (breast cell) ( 58 ) , MDA-MB-231 (breast cell) ( 1 , 4 , 51 ) , mononuclear ( 31 ) , MUTZ-5 (B lymphocyte) ( 35 ) , MV4-11 (macrophage) ( 33 , 34 ) , myeloid ( 48 ) , natural killer cell-blood ( 32 ) , NCI-H1299 (pulmonary) ( 18 ) , NCI-H838 (pulmonary) ( 9 ) , neutrophil ( 54 ) , NK92 (natural killer cell) ( 19 ) , OCI/AML3 (myeloid) ( 39 ) , osteoclast ( 17 ) , P116 (T lymphocyte) ( 20 ) , PC-12 (chromaffin) ( 8 , 45 ) , RAW 264 (macrophage) ( 56 ) , SEM (B lymphocyte) ( 37 ) , stomach ( 24 ) , SYF (fibroblast) ( 45 ) , T lymphocyte ( 3 ) , T lymphocyte-blood ( 42 ) , T47D (breast cell) ( 58 ) , thymus ( 16 ) , U2OS (bone cell) ( 12 )

Upstream Regulation
Regulatory protein:
Fyn (human) ( 20 ) , HS1 (human) ( 32 ) , PSD-95 (human) ( 5 ) , RHOU (human) ( 18 ) , ZAP70 (human) ( 20 )
Putative in vivo kinases:
Pyk2 (human) ( 8 , 45 , 46 ) , Src (human) ( 41 )
Kinases, in vitro:
Src (human) ( 41 )
Treatments:
2-deoxyglucose ( 28 ) , AG17 ( 42 ) , aminoxyacetic_acid ( 2 ) , anti-CD3 ( 20 ) , anti-CD3/CD28 ( 3 , 52 ) , anti-VE-cadherin ( 40 ) , BAPTA-AM ( 9 , 20 , 53 ) , calcitonin ( 55 ) , calphostin_C ( 41 , 53 ) , CXCL12 ( 47 , 51 ) , damnacanthal ( 20 ) , depolarization ( 8 , 45 ) , DPI ( 53 ) , EGF ( 49 ) , EGTA ( 20 ) , ephrin_A1 ( 42 ) , fibronectin ( 32 ) , GF109203X ( 9 ) , H-89 ( 9 ) , H2O2 ( 2 , 53 ) , heregulin ( 58 ) , hyaluronan ( 17 ) , ICAM-1 ( 3 , 32 ) , IL-15 ( 19 ) , ionomycin ( 55 ) , latrunculin_B ( 20 ) , mechanical stress ( 53 ) , miRNA ( 4 ) , Mn(2+) ( 41 ) , NAC ( 7 , 53 ) , NKH_477 ( 8 ) , NMDA ( 5 ) , PACAP ( 9 ) , PF-431396 ( 7 ) , phorbol_ester ( 31 , 32 , 41 , 55 ) , piceatannol ( 41 ) , PP1 ( 41 , 53 ) , PP2 ( 20 , 44 ) , proepithelin ( 54 ) , RGD ( 41 ) , siRNA ( 32 ) , sodium sulfide ( 2 ) , TNF ( 54 ) , U73122 ( 9 ) , vanadate ( 41 ) , VEGF ( 47 , 56 ) , VIP ( 9 ) , vitronectin ( 41 ) , wortmannin ( 20 , 41 ) , Y27632 ( 41 )

Downstream Regulation
Effects of modification on Pyk2:
enzymatic activity, induced ( 1 , 7 , 8 , 31 , 38 , 46 , 57 ) , intracellular localization ( 40 ) , molecular association, regulation ( 19 , 58 ) , phosphorylation ( 46 ) , protein degradation ( 19 ) , ubiquitination ( 19 )
Effects of modification on biological processes:
cell cycle regulation ( 47 ) , cell motility, altered ( 58 )
Induce interaction with:
HER2 (human) ( 58 ) , RASA1 (human) ( 58 ) , SOCS2 (human) ( 19 ) , Src (human) ( 58 )

Disease / Diagnostics Relevance
Relevant diseases:
breast cancer ( 58 )

References 

1

Genna A, et al. (2018) Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells. J Cell Biol 217, 375-395
29133485   Curated Info

2

Bibli SI, et al. (2017) Hydrogen Sulfide Preserves Endothelial Nitric Oxide Synthase Function by Inhibiting Proline-Rich Kinase 2: Implications for Cardiomyocyte Survival and Cardioprotection. Mol Pharmacol 92, 718-730
29030392   Curated Info

3

Eppler FJ, Quast T, Kolanus W (2017) Dynamin2 controls Rap1 activation and integrin clustering in human T lymphocyte adhesion. PLoS One 12, e0172443
28273099   Curated Info

4

Sundararajan V, et al. (2015) The ZEB1/miR-200c feedback loop regulates invasion via actin interacting proteins MYLK and TKS5. Oncotarget 6, 27083-96
26334100   Curated Info

5

Zhao C, et al. (2015) The Upregulation of NR2A-Containing N-Methyl-D-Aspartate Receptor Function by Tyrosine Phosphorylation of Postsynaptic Density 95 Via Facilitating Src/Proline-Rich Tyrosine Kinase 2 Activation. Mol Neurobiol 51, 500-11
24981431   Curated Info

6

Kinoshita Y, et al. (2014) Role for NUP62 depletion and PYK2 redistribution in dendritic retraction resulting from chronic stress. Proc Natl Acad Sci U S A 111, 16130-5
25349423   Curated Info

7

Das JK, Felty Q (2014) PCB153-Induced Overexpression of ID3 Contributes to the Development of Microvascular Lesions. PLoS One 9, e104159
25090023   Curated Info

8

Faure C, Ramos M, Girault JA (2013) Pyk2 cytonuclear localization: mechanisms and regulation by serine dephosphorylation. Cell Mol Life Sci 70, 137-52
22802128   Curated Info

9

Moody TW, Di Florio A, Jensen RT (2012) PYK-2 is Tyrosine Phosphorylated after Activation of Pituitary Adenylate Cyclase Activating Polypeptide Receptors in Lung Cancer Cells. J Mol Neurosci 48, 660-6
22581436   Curated Info

10

Mulhern D (2011) CST Curation Set: 13267; Year: 2011; Biosample/Treatment: cell line, K-562/untreated &'||' untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

11

Mulhern D (2011) CST Curation Set: 13268; Year: 2011; Biosample/Treatment: cell line, K-562/untreated &'||' untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

12

Malik SA, et al. (2011) BH3 mimetics activate multiple pro-autophagic pathways. Oncogene 30, 3918-29
21460857   Curated Info

13

Ren H (2011) CST Curation Set: 11772; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Ren H (2011) CST Curation Set: 11773; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Ren H (2011) CST Curation Set: 11774; Year: 2011; Biosample/Treatment: cell line, RP91/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Li Y (2011) CST Curation Set: 10458; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

17

Pivetta E, et al. (2011) Blood-derived human osteoclast resorption activity is impaired by Hyaluronan-CD44 engagement via a p38-dependent mechanism. J Cell Physiol 226, 769-79
20799279   Curated Info

18

Alan JK, et al. (2010) Regulation of the Rho family small GTPase Wrch-1/RhoU by C-terminal tyrosine phosphorylation requires Src. Mol Cell Biol 30, 4324-38
20547754   Curated Info

19

Lee SH, et al. (2010) Suppressor of cytokine signaling 2 regulates IL-15-primed human NK cell function via control of phosphorylated Pyk2. J Immunol 185, 917-28
20543098   Curated Info

20

Collins M, et al. (2010) The T cell receptor-mediated phosphorylation of Pyk2 tyrosines 402 and 580 occurs via a distinct mechanism than other receptor systems. J Leukoc Biol 87, 691-701
20028775   Curated Info

21

Possemato A (2010) CST Curation Set: 9379; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

22

Guo A (2010) CST Curation Set: 9181; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

Possemato A (2009) CST Curation Set: 8804; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

24

Ren H (2009) CST Curation Set: 8025; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

25

Possemato A (2009) CST Curation Set: 8189; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

26

Possemato A (2009) CST Curation Set: 7996; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

27

Possemato A (2009) CST Curation Set: 7997; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

28

Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33
19574224   Curated Info

29

Possemato A (2009) CST Curation Set: 7999; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

30

Moritz A (2009) CST Curation Set: 6446; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

31

Wang M, Sun H, Zhang W, Zhang Y (2009) Functional activation of proline-rich tyrosine kinase2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. BMC Musculoskelet Disord 10, 141
19919693   Curated Info

32

Butler B, Kastendieck DH, Cooper JA (2008) Differently phosphorylated forms of the cortactin homolog HS1 mediate distinct functions in natural killer cells. Nat Immunol 9, 887-97
18587398   Curated Info

33

Moritz A (2006) CST Curation Set: 1893; Year: 2006; Biosample/Treatment: cell line, MV4-11/Flt3 inhibitor; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

34

Moritz A (2006) CST Curation Set: 1895; Year: 2006; Biosample/Treatment: cell line, MV4-11/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

35

Gu T (2006) CST Curation Set: 1873; Year: 2006; Biosample/Treatment: cell line, MUTZ-5/untreated; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

36

Rikova K (2006) CST Curation Set: 1864; Year: 2006; Biosample/Treatment: cell line, 5637/serum starved; Disease: bladder cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

37

Moritz A (2006) CST Curation Set: 1822; Year: 2006; Biosample/Treatment: cell line, SEM/-; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

38

Le Boeuf F, Houle F, Sussman M, Huot J (2006) Phosphorylation of focal adhesion kinase (FAK) on Ser732 is induced by rho-dependent kinase and is essential for proline-rich tyrosine kinase-2-mediated phosphorylation of FAK on Tyr407 in response to vascular endothelial growth factor. Mol Biol Cell 17, 3508-20
16760434   Curated Info

39

Gu T (2006) CST Curation Set: 1506; Year: 2006; Biosample/Treatment: cell line, OCI/AML3/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

40

van Buul JD, et al. (2005) Proline-rich tyrosine kinase 2 (Pyk2) mediates vascular endothelial-cadherin-based cell-cell adhesion by regulating beta-catenin tyrosine phosphorylation. J Biol Chem 280, 21129-36
15778498   Curated Info

41

Butler B, Blystone SD (2005) Tyrosine phosphorylation of beta3 integrin provides a binding site for Pyk2. J Biol Chem 280, 14556-62
15695828   Curated Info

42

Aasheim HC, Delabie J, Finne EF (2005) Ephrin-A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. Blood 105, 2869-76
15585656   Curated Info

43

Possemato A (2004) CST Curation Set: 7998; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

44

Wei L, Yang Y, Zhang X, Yu Q (2004) Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Oncogene 23, 9052-61
15489898   Curated Info

45

Park SY, Avraham HK, Avraham S (2004) RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Src-independent manner. J Biol Chem 279, 33315-22
15166227   Curated Info

46

Meyer AN, Gastwirt RF, Schlaepfer DD, Donoghue DJ (2004) The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation. J Biol Chem 279, 28450-7
15105428   Curated Info

47

Kuwabara K, et al. (2004) Differential regulation of cell migration and proliferation through proline-rich tyrosine kinase 2 in endothelial cells. Endocrinology 145, 3324-30
15070849   Curated Info

48

Recher C, et al. (2004) Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 64, 3191-7
15126359   Curated Info

49

Shi CS, Kehrl JH (2004) Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation. J Biol Chem 279, 17224-31
14963038   Curated Info

50

Chandhoke SK, et al. (2004) Beta 3 integrin phosphorylation is essential for Arp3 organization into leukocyte alpha V beta 3-vitronectin adhesion contacts. J Cell Sci 117, 1431-41
14996908   Curated Info

51

Fernandis AZ, et al. (2004) Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 23, 157-67
14712221   Curated Info

52

Sakakibara A, Hattori S, Nakamura S, Katagiri T (2003) A novel hematopoietic adaptor protein, Chat-H, positively regulates T cell receptor-mediated interleukin-2 production by Jurkat cells. J Biol Chem 278, 6012-7
12486027   Curated Info

53

Cheng JJ, Chao YJ, Wang DL (2002) Cyclic strain activates redox-sensitive proline-rich tyrosine kinase 2 (PYK2) in endothelial cells. J Biol Chem 277, 48152-7
12368297   Curated Info

54

Zhu J, et al. (2002) Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111, 867-78
12526812   Curated Info

55

Zhang Z, et al. (2002) Calcitonin induces dephosphorylation of Pyk2 and phosphorylation of focal adhesion kinase in osteoclasts. Bone 31, 359-65
12231407   Curated Info

56

Matsumoto Y, et al. (2002) Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol 168, 5824-31
12023386   Curated Info

57

Katagiri T, et al. (2000) Protein-tyrosine kinase Pyk2 is involved in interleukin-2 production by Jurkat T cells via its tyrosine 402. J Biol Chem 275, 19645-52
10867021   Curated Info

58

Zrihan-Licht S, et al. (2000) RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion. Oncogene 19, 1318-28
10713673   Curated Info